Study summary
Zipalertinib shrank exon 20 insertion tumors in about a third of patients
35.2%of tumors shrank
What was tested
Zipalertinib, an EGFR pill designed for the less common exon 20 insertion mutations, in people already treated with chemotherapy, with or without amivantamab. No comparison group.
What they found
- Tumors shrank in 35.2%, for a median of 8.8 months.
- In people with brain metastases, 30.9% responded.
- Severe side effects were uncommon (anemia 7%).
What it means
Adds a pill option for exon 20 insertions; a first-line trial with chemotherapy is under way.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.